EQL Pharma out-licenses Methenamine Hippurate to Dr. Pfleger Arzneimittel for the German market
EQL has entered into an exclusive license agreement for the German market for EQL’s product Methenamine Hippurate with Dr. Pfleger Arzneimittel, a leading German company in urology and gynaecology.Methenamine Hippurate is a medicine indicated for the prophylaxis of recurrent urinary tract infection (rUTI). Methenamine hippurate was launched by EQL in Sweden in 2019, in the UK (via partner) in 2020 and in Norway in 2021. EQL's ambition is to offer Methenamine to all other interesting markets in Europe via out-licensing. Methenamine hippurate is the only substance that is non-inferior to